Zydus and Dr. Reddy's announce licensing agreement for co?marketing of Pertuzumab biosimilar

Ascentage Pharma closes US$ 75 million equity investment by Takeda

Ascentage Pharma announces confidential submission of draft registration statement for proposed IPO

Truqap plus Faslodex approved in the EU for patients with advanced ER-positive breast cancer

Approval based on CAPItello-291 results which showed this combination reduced the risk of disease progression or death by 50% vs. Faslodex alone in a biomarker-altered population

Bristol Myers Squibb receives USFDA accelerated approval of Krazati in combination with Cetuximab for CRC

Second FDA approval for KRAZATI - reinforcing its potential across tumor types

Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide

Zealand Pharma anticipates initiation of a Phase 2b clinical trial in H2 2024

Ascentage Pharma aims global license agreement with Takeda for Olverembatinib

Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other than China and a few other areas

Cipla EU to invest an additional € 3 million in Ethris

Cipla had earlier invested € 15 million in Ethris in 2022

Jubilant Draximage to invest US$ 50 million to expand its PET radiopharmacy network

Jubilant's Radiopharma Business to expand positron emission tomography radiopharmacy network

Sun Pharma and Moebius Medical present Phase 2b study on MM-II

There is an urgent need for more therapeutic treatment options for patients with painful osteoarthritis

Lilly's tirzepatide was superior to placebo for MASH resolution

SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously published in The New England Journal of Medicine